Acurx Announces Positive Phase 2b Results Showing 100% of Pa

All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure at end of treatment remained free of C. difficile Infection recurrence through one month after EOT, for a Sustained...

Related Keywords

United States , America , Kevin Garey , Stuart Johnson , Robertj Deluccia , Davidp Luci , Acurx Pharmaceuticals Inc , Infectious Diseases Society Of America , University Of Houston College Pharmacy , Data Monitoring Committee , Exchange Commission On Form , Drug Administration , Nasdaq , Company Ph , Trial Oversight Committee , Society Or Healthcare Epidemiology Of America , Exchange Commission , Company Scientific Advisory Board , Loyola University Infectious Disease , European Medicines Agency , Acurx Pharmaceuticals , Prnewswire Acurx Pharmaceuticals Inc , Clinical Cure , Sustained Clinical Cure , Extended Clinical Cure , Houston College , Principal Investigator , Acurx Scientific Advisory Board , Loyola University , Infectious Disease , Executive Chairman , Ibezapolstat Phase , Scientific Advisory Board , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , Bile Acid , Private Securities Litigation Reform Act , Markets ,